Home > Dermatology > Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis

Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
WPPAC 2021
Trial
Phase 3, POETYK PSO-1, POETYK PSO-2
Based on the findings of the phase 3 POETYK PSO-1 and PSO-2 trials, deucravacitinib, a once-daily, oral, selective tyrosine kinase (TYK)2 inhibitor, has the potential to become an efficacious and well-tolerated treatment of choice for patients with moderate-to-severe plaque psoriasis [1]. TYK2 is an intracellular kinase that mediates IL-23, IL-12, and type 1 interferon signalling in the pathogenesis of psoriasis. Deucravacitinib has a unique mechanism of action distinct from JAK1/2/3 inhibitors. It achieves a high degree of selectivity by uniquely binding to the TYK2 regulatory domain, rather than to the active domain of TYK2, which is structurally distinct from the regulatory domains of JAK1/2/3 [2]. Deucravacitinib previously demonstrated efficacy and tolerability in phase 2 trials in patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis [3,4]. POETYK PSO-1 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on